Companies To Watch

The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering an interesting story involving useful business lessons.

More From Companies To Watch


  • Daniel Skovronsky – From Grad Student, To CEO, To Big Pharma

    Daniel Skovronsky, M.D., Ph.D., is the SVP of clinical and product development at Eli Lilly and Company. But prior to taking on this role, he held the title of CEO of Avid Radiopharmaceuticals — a company he founded in Philadelphia while still a graduate student at the University of Pennsylvania. This article explores some of the differences between this executives past and present roles, and is a good prequel to the upcoming article that explores how he went about building a $300 million company.

  • Does The Biopharmaceutical Industry Need To Broaden Its Horizons?

    When I interviewed Axovant Sciences CEO David Hung, one of the questions posed was sparked by our discussion of his experience at Pro-Duct Health and his invention of a microcatheter for early detection of ductal breast cancer in women. As he explained his medical device invention, Hung commented, “I don’t want to be just medicines, or just devices, or anything like that.”

  • What Might Be The Best Predictor Of Future Performance At Axovant Sciences?

    Chief Editor Rob Wright recently conducted an in-person interview with David Hung, formerly of Medivation and current  CEO of Axovant Sciences. Though many may credit the FDA’s approval of Medivation’s Xtandi (enzalutamide) as being the primary driver behind Hung’s rise, Wright argues that there are a number of other predictors that should be evaluated when anticipating future success.

More From Beyond The Printed Page


  • Why <em>Every</em> Company Needs A Bio Strategy
    Why Every Company Needs A Bio Strategy

    Today we stand on the precipice overlooking a new frontier — the century of biology, and businesses of all kinds need to be prepared to not only embrace what is coming, but have a strategy for how to leverage biology for the betterment of their businesses and the good of the planet.

  • What Is BIO Hoping To See Among Session Submissions For 2018?
    What Is BIO Hoping To See Among Session Submissions For 2018?

    Life Science Leader Chief Editor Rob Wright is cochairing the 2018 BIO educational program planning committee. In this blog he talks about why this was the earliest the planning committee has ever met and what you can do to submit interesting and novel session proposals that will get the attention of the committee.

More From Life Science Leader Blogs